A Multicenter, Randomized, Phase 3 Trial of a Novel Autologous Therapeutic Vaccine (Vitespen) Vs. Observation as Adjuvant Therapy in Patients at High Risk of Recurrence After Nephrec- tomy for Renal Cell Carcinoma